Share:
HIV i-Base overview
Three presentations at CROI 2026 covered extended follow-up for lenacapavir PrEP in the large, randomised, phase 3 PURPOSE-1 and -2 studies, including details on new cases of HIV acquisition. All abstracts, posters and webcasts for the reported studies are now available online and hyperlinked in the references.
Read the full overview here.
CROI 2026: Full coverage
Source : HIV i-Base
Related HIV and Co-Infections News
-
aidsmap: DoxyPEP halves overall syphilis cases, with possible indirect benefits for women
-
[Press release] US and Global Fund expand commitment to long-acting HIV prevention as country rollout of lenacapavir accelerates
-
University of Manchester: Scientists develop a cheaper and more sustainable way to manufacture breakthrough HIV drug lenacapavir
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.